Reuters logo
in a month
BRIEF-Zynerba Pharma achieves target enrollment in exploratory phase 2 trial of ZYN002 in fragile X syndrome
June 8, 2017 / 11:41 AM / in a month

BRIEF-Zynerba Pharma achieves target enrollment in exploratory phase 2 trial of ZYN002 in fragile X syndrome

1 Min Read

June 8 (Reuters) - Zynerba Pharmaceuticals Inc

* Zynerba Pharmaceuticals achieves target enrollment in exploratory phase 2 trial of ZYN002 in fragile X syndrome Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below